New Haven-based bioscience firms Bexorg, Biohaven agree to collaborate
Courtesy of Engine Ventures, Doug Levy
Bexorg co-founders Nenad Sestan, left, and Zvonimir Vrselja.
Two New Haven-based bioscience firms have announced an agreement to collaborate on research and development of therapies for central nervous system disorders (CNS).
Bexorg Inc., a techbio company based at 290 Congress Ave. that is working to decode the human brain and advance new therapies for CNS disorders, said Tuesday it has agreed to a research collaboration with biopharmaceutical firm Biohaven Ltd., based at 215 Church St.
Financial terms of the collaboration were not disclosed.
The collaboration will use Bexorg’s whole-brain discovery platform, which the company describes as the only technology “capable of perfusing isolated cadaver human and pig brains with custom-made artificial blood, restoring metabolic and molecular activity for prolonged periods.” Using it, Bexorg said, can provide insights into disease-relevant states.
Bexorg said it’s building the largest and most physiologically relevant datasets in human neurodegeneration to enable machine learning and AI-centered CNS drug discovery and development.
Under the agreement, data generated from the platform may also potentially identify novel biomarkers to inform clinical trials.
“Our technology enables preclinical testing of almost any therapeutic in metabolically active whole human brains, whether diseased or non-diseased, providing a significant advantage over any other preclinical model in neuroscience,” said Dr. Zvonimir Vrselja, CEO and co-founder of Bexorg. “We are thrilled to team up with Biohaven to help advance two preclinical programs and potentially unlock a faster, more precise path to new CNS therapies.”
Biohaven Ltd. is the company that remained after the original Biohaven sold its migraine therapeutic assets to pharmaceutical giant Pfizer Inc. in 2022, in a deal valued at $13 billion.
In April, Biohaven announced that New York-based Oberland Capital had agreed to invest up to $600 million in the company, and that the additional capital will provide significant financial resources for ongoing clinical trials across the company's full development portfolio.
Most Recent
Most Recent
0 Comments